We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Citations Search

Sort By:

Adv. Sci. (Weinh) 5, 1800368. Self-triggered apoptosis enzyme prodrug therapy (STAEPT): Enhancing targeted therapies via recurrent bystander killing effect by exploiting caspase-cleavable linker. 2018

Chung, S.W., Choi, J.U., Cho, Y.S., Kim, H.R., Won, T.H., Dimitrion, P., Jeon, O.C., Kim, S.W., Kim, I.S., Kim, S.Y. and Byun, Y.

Notes: Tumors are heterogeneous and contain cells with distinct genetic backgrounds and phenotypes. Targeted cancer therapies can selectively kill specific cancer cells, but due to tumor heterogeneity, many of these therapies fail to have lasting outcomes. Self-triggered apoptosis enzyme prodrug therapy (STAEPT) targets integrin αvβ3 cancer cells, and upon entering cells, is cleaved by caspases. The cleaved cytotoxin is released and leads to neighboring cell apoptosis. The VivoGlo™ Caspase-3/7 Substrate is used to monitor caspase expression in cells. (5140)

Expand Full Notes »